Inclusion Criteria:
- Written informed consent must be obtained before any assessment was
performed.
- Men and women ≥ 18 years of age.
- LVEF ≤ 40% subjects who were candidates for on-label
sacubitril/valsartan treatment per standard of care.
- New York Heart Association (NYHA) Functional class II-IV.
- LVEF ≤ 40% via any local measurement within the past 6 months using
echocardiography. If a subject was on a loop diuretic, they must be on
a stable dose for 2 weeks prior to baseline.